OncoMatch/Clinical Trials/NCT06209580

AMT-253 in Patients With Advanced Solid Tumours

Is NCT06209580 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AMT-253 for for malignant melanoma.

Phase 1/2RecruitingMultitude Therapeutics Inc.NCT06209580Data as of May 2026

Treatment: AMT-253 for — This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Cannot have received: any agent that has the same target

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Patients must have adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify